Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MCK
MCK logo

MCK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
875.070
Open
869.950
VWAP
863.90
Vol
689.19K
Mkt Cap
105.36B
Low
856.435
Amount
595.39M
EV/EBITDA(TTM)
17.56
Total Shares
122.49M
EV
110.16B
EV/OCF(TTM)
10.51
P/S(TTM)
0.27
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
Show More

Events Timeline

(ET)
2026-03-05
08:20:00
McKesson CFO Britt Vitalone Retires, Kenny Cheung to Succeed
select
2026-02-05 (ET)
2026-02-05
12:10:00
McKesson Stock Rises 15.5% to $949.55
select
2026-02-05
10:10:00
McKesson Stock Rises 14.1% to $937.72
select
2026-02-05
10:00:00
McKesson and Others See Notable Stock Gains
select

News

NASDAQ.COM
9.5
03-20NASDAQ.COM
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
  • Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
  • Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
  • Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
  • Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
CNBC
2.0
03-19CNBC
Stocks Decline as Oil Prices Surge Following Iran's Attack
  • Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
  • Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
  • Nvidia Stock Analysis: Jim Cramer reiterated his
CNBC
8.5
03-18CNBC
Jim Cramer's Trust Increases Stake in Cardinal Health
  • Increased Stake: Jim Cramer's Charitable Trust purchased 50 shares of Cardinal Health (CAH) at approximately $214 each on Wednesday, raising its total holdings to 450 shares and increasing the portfolio weighting from 2.27% to 2.55%, reflecting confidence in the company.
  • Market Reaction: Since the onset of the Middle East conflict, energy prices and stocks have shown an inverse relationship, with rising oil prices leading to stock sell-offs and concerns about inflation, as evidenced by the S&P 500's decline of over 0.5%.
  • Financial Outlook: Cardinal Health generates nearly 100% of its revenue in the U.S., and management indicated that the recent commodity price spike will have an immaterial impact on its fiscal year 2026 earnings, showcasing its resilience and prompting investors to accumulate shares during market weakness.
  • Industry Dynamics: Despite the healthcare sector's poor performance this month and the retirement of two CFOs raising concerns, Cencora's reaffirmation of its financial guidance has alleviated fears of an impending shortfall, indicating stability within the industry.
Marketbeat
2.0
03-15Marketbeat
Three Stocks Likely to Announce Upcoming Stock Splits
  • Stock Splits Overview: Stock splits are actions taken by companies to make their shares more affordable for retail investors, typically occurring after periods of significant growth or innovation.

  • Investor Psychology: The intrinsic value of a company remains unchanged after a stock split, but investor psychology plays a crucial role in driving short-term performance, as lower-priced shares may attract more buyers.

  • Examples of Companies: Companies like Costco and Walmart have announced stock splits, with Costco's stock trading over $1,000 per share and Walmart's split planned for January 2024, reflecting strong share price growth.

  • Future Stock Splits: Analysts suggest that companies like KLA Corporation and Eli Lilly may consider stock splits in the future, driven by their strong growth stories and increasing share prices, which could benefit investors.

CNBC
4.5
03-07CNBC
Stocks Decline Amid Middle East Conflict and Mixed Economic Data
  • Escalating Middle East Conflict: The U.S. and Israel's bombing of Iran has pressured global stocks, with the S&P 500 dropping 2% last week, while oil prices surged to $90 per barrel, marking a 35% weekly gain, the largest since 1983, indicating potential economic repercussions.
  • Mixed Economic Data: Although the ADP report indicated a rise of 63,000 private sector jobs in February, surpassing expectations, the subsequent nonfarm payroll report revealed an increase in the unemployment rate to 4.4%, highlighting emerging job losses due to AI and creating uncertainty about the economic outlook.
  • Earnings Impact: Broadcom exceeded earnings expectations, resulting in a 3.4% stock increase, while Corning's shares fell nearly 7% following comments from Broadcom's CEO that dampened optimism about fiber-optic technology, reflecting market volatility in tech sectors.
  • Investment Strategy Adjustments: Amid market fluctuations, the investment club increased its position in Cardinal Health and exited BlackRock entirely due to rising private credit concerns, demonstrating a proactive approach to navigating the current market landscape.
Marketbeat
8.0
03-06Marketbeat
Three Dividend Growth Stocks Steadily Increasing Their Payouts
  • Market Volatility and Investment Strategy: With increasing market volatility, investors are considering a shift towards more defensive investment strategies, particularly focusing on dividend stocks that have a history of stable increases.

  • Broadcom's Performance: Broadcom Inc. is highlighted as a strong player in the AI and semiconductor sectors, with significant revenue growth and a consistent history of dividend increases, making it an attractive option for investors.

  • McKesson's Resilience: McKesson Corporation is noted for its stable dividend payments and growth potential, despite short-term challenges, supported by its diversified business model in healthcare.

  • Amphenol's Dividend Growth: Amphenol Corporation has demonstrated a strong track record of dividend increases, positioning itself as a reliable investment option, with expectations for continued earnings growth in the coming year.

Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
Wall Street analysts forecast MCK stock price to rise
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
880.00
Averages
942.83
High
1000.00
Current: 0.000
sliders
Low
880.00
Averages
942.83
High
1000.00
BofA
Buy
upgrade
$970
AI Analysis
2026-03-06
Reason
BofA
Price Target
$970
AI Analysis
2026-03-06
upgrade
Buy
Reason
BofA raised the firm's price target on McKesson (MCK) to $1,040 from $970 and keeps a Buy rating on the shares. McKesson "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Barclays
NULL
to
Overweight
maintain
$960
2026-02-18
Reason
Barclays
Price Target
$960
2026-02-18
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on McKesson to $1,050 from $960 and keeps an Overweight rating on the shares. The firm expects the stock to "remain in favor" as investors seek "pockets of safety within healthcare," but notes McKesson is now trading at a 15% premium to its three-year average.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MCK
Unlock Now

Valuation Metrics

The current forward P/E ratio for McKesson Corp (MCK.N) is 20.01, compared to its 5-year average forward P/E of 14.90. For a more detailed relative valuation and DCF analysis to assess McKesson Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
14.90
Current PE
20.01
Overvalued PE
18.14
Undervalued PE
11.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.33
Current EV/EBITDA
15.16
Overvalued EV/EBITDA
13.65
Undervalued EV/EBITDA
9.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.18
Current PS
0.24
Overvalued PS
0.21
Undervalued PS
0.15

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

good long term option call
Intellectia · 10 candidates
Market Cap: >= 100.00BMarket Cap Category: largeAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Optionable: TrueAnnual Revenue Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
KLAC logo
KLAC
KLA Corp
198.11B
ANET logo
ANET
Arista Networks Inc
170.74B
APH logo
APH
Amphenol Corp
160.62B
ADI logo
ADI
Analog Devices Inc
152.41B
WELL logo
WELL
Welltower Inc
136.06B
ENB logo
ENB
Enbridge Inc
118.20B
what to buy or sell now
Intellectia · 39 candidates
Market Cap: >= 20.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX, DJI
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
639.72B
CMI logo
CMI
Cummins Inc
74.44B
HAL logo
HAL
Halliburton Co
29.18B
NEM logo
NEM
Newmont Corporation
124.54B
AEE logo
AEE
Ameren Corp
30.41B
REGN logo
REGN
Regeneron Pharmaceuticals Inc
78.93B
atocks to buy tomoroow
Intellectia · 46 candidates
Moving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $25.00Is Index Component: GSPC, NDXAnnual Revenue Yoy Growth: >= 10.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
MCK logo
MCK
McKesson Corp
120.94B
PWR logo
PWR
Quanta Services Inc
83.96B
BALL logo
BALL
Ball Corp
17.86B
IRM logo
IRM
Iron Mountain Inc
32.05B
NEM logo
NEM
Newmont Corporation
141.42B
NFLX logo
NFLX
Netflix Inc
406.34B
strong buy best stock to trade next week ?
Intellectia · 84 candidates
Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNASOne Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
ECL logo
ECL
Ecolab Inc
86.95B
ASND logo
ASND
Ascendis Pharma A/S
14.47B
WBS logo
WBS
Webster Financial Corp
11.63B
NU logo
NU
Nu Holdings Ltd
72.74B
MP logo
MP
MP Materials Corp
10.46B
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.94T
Featured Screeners
Intellectia · 45 candidates
Market Cap: >= 20.00BEps 5yr Cagr: >= 15Pe Ttm: 15 - 30Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.94T
JPM logo
JPM
JPMorgan Chase & Co
809.92B
JNJ logo
JNJ
Johnson & Johnson
598.69B
MU logo
MU
Micron Technology Inc
464.13B
NVS logo
NVS
Novartis
321.75B
HSBC logo
HSBC
HSBC Holdings PLC
320.01B
what should I buy to make some quick cash
Intellectia · 29 candidates
Market Cap: >= 2.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
RELY logo
RELY
Remitly Global Inc
2.85B
AVAV logo
AVAV
AeroVironment Inc
13.25B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
16.41B
LBRT logo
LBRT
Liberty Energy Inc
4.39B
VIST logo
VIST
Vista Energy SAB de CV
5.78B
GLBE logo
GLBE
Global-E Online Ltd
5.91B
what should I buy with 10k today
Intellectia · 72 candidates
Market Cap: >= 10.00BQuarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 10 - 35Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
AMZN logo
AMZN
Amazon.com Inc
2.13T
META logo
META
Meta Platforms Inc
1.62T
V logo
V
Visa Inc
598.64B
MU logo
MU
Micron Technology Inc
463.33B
welche us Aktien soll ich heute kaufen?
Intellectia · 53 candidates
Market Cap: >= 0Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
JPM logo
JPM
JPMorgan Chase & Co
813.77B
MU logo
MU
Micron Technology Inc
439.39B
MS logo
MS
Morgan Stanley
287.52B
GS logo
GS
Goldman Sachs Group Inc
277.15B
MRK logo
MRK
Merck & Co Inc
266.87B
AXP logo
AXP
American Express Co
247.25B
Top Biotechnology/Health Tech
Intellectia · 82 candidates
Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $10.00Annual Eps Yoy Growth: >= 10.0%Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
1.02T
AZN logo
AZN
AstraZeneca PLC
280.73B
NVS logo
NVS
Novartis AG
278.44B
MCK logo
MCK
McKesson Corp
101.61B
ARGX logo
ARGX
argenx SE
50.52B
ALNY logo
ALNY
Alnylam Pharmaceuticals Inc
48.28B
show me strong buy stocks
Intellectia · 28 candidates
Market Cap: 10.00B - 200.00BAnalyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Pe Ttm: 10 - 30Annual Revenue Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
BLK logo
BLK
BlackRock Inc
183.61B
UBER logo
UBER
Uber Technologies Inc
175.08B
NEM logo
NEM
Newmont Corporation
129.76B
MCK logo
MCK
McKesson Corp
101.61B
ICE logo
ICE
Intercontinental Exchange Inc
98.01B
WDC logo
WDC
Western Digital Corp
82.71B

Whales Holding MCK

P
Pacer Advisors, Inc.
Holding
MCK
+8.18%
3M Return
B
Boston Partners Global Investors, Inc.
Holding
MCK
+5.70%
3M Return
D
Danske Bank A/S
Holding
MCK
+3.70%
3M Return
D
Distillate Capital Partners LLC
Holding
MCK
+1.19%
3M Return
B
Brighthouse Investment Advisers, LLC
Holding
MCK
+0.75%
3M Return
A
Anchor Capital Advisors LLC
Holding
MCK
+0.19%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is McKesson Corp (MCK) stock price today?

The current price of MCK is 860.19 USD — it has increased 0

What is McKesson Corp (MCK)'s business?

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

What is the price predicton of MCK Stock?

Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is McKesson Corp (MCK)'s revenue for the last quarter?

McKesson Corp revenue for the last quarter amounts to 106.16B USD, increased 11.40

What is McKesson Corp (MCK)'s earnings per share (EPS) for the last quarter?

McKesson Corp. EPS for the last quarter amounts to 9.59 USD, increased 38.18

How many employees does McKesson Corp (MCK). have?

McKesson Corp (MCK) has 43000 emplpoyees as of March 31 2026.

What is McKesson Corp (MCK) market cap?

Today MCK has the market capitalization of 105.36B USD.